• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

OSIRIS:肿瘤学中用于数据共享和互操作的最小数据集。

OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology.

机构信息

Direction des Données, Institut Curie, Paris, France.

Bioinformatics and AI Unit, Institut Bergonié, Bordeaux, France.

出版信息

JCO Clin Cancer Inform. 2021 Mar;5:256-265. doi: 10.1200/CCI.20.00094.

DOI:10.1200/CCI.20.00094
PMID:33720747
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8140800/
Abstract

PURPOSE

Many institutions throughout the world have launched precision medicine initiatives in oncology, and a large amount of clinical and genomic data is being produced. Although there have been attempts at data sharing with the community, initiatives are still limited. In this context, a French task force composed of Integrated Cancer Research Sites (SIRICs), comprehensive cancer centers from the Unicancer network (one of Europe's largest cancer research organization), and university hospitals launched an initiative to improve and accelerate retrospective and prospective clinical and genomic data sharing in oncology.

MATERIALS AND METHODS

For 5 years, the OSIRIS group has worked on structuring data and identifying technical solutions for collecting and sharing them. The group used a multidisciplinary approach that included weekly scientific and technical meetings over several months to foster a national consensus on a minimal data set.

RESULTS

The resulting OSIRIS set and event-based data model, which is able to capture the disease course, was built with 67 clinical and 65 omics items. The group made it compatible with the HL7 Fast Healthcare Interoperability Resources (FHIR) format to maximize interoperability. The OSIRIS set was reviewed, approved by a National Plan Strategic Committee, and freely released to the community. A proof-of-concept study was carried out to put the OSIRIS set and Common Data Model into practice using a cohort of 300 patients.

CONCLUSION

Using a national and bottom-up approach, the OSIRIS group has defined a model including a minimal set of clinical and genomic data that can be used to accelerate data sharing produced in oncology. The model relies on clear and formally defined terminologies and, as such, may also benefit the larger international community.

摘要

目的

世界上许多机构都在肿瘤学领域开展了精准医学计划,并产生了大量的临床和基因组数据。尽管已经有与社区共享数据的尝试,但计划仍然有限。在这种情况下,由综合癌症研究机构(SIRICs)、Unicancer 网络(欧洲最大的癌症研究组织之一)的综合癌症中心和大学医院组成的法国工作队发起了一项倡议,以改善和加速肿瘤学中的回顾性和前瞻性临床和基因组数据共享。

材料和方法

五年来,OSIRIS 小组致力于构建数据和确定收集和共享数据的技术解决方案。该小组采用了多学科方法,包括数月来每周举行的科学和技术会议,以促进国家对最小数据集的共识。

结果

由此产生的 OSIRIS 集和基于事件的数据模型,能够捕获疾病过程,由 67 个临床和 65 个组学项目构建而成。该小组使其与 HL7 Fast Healthcare Interoperability Resources (FHIR) 格式兼容,以实现最大的互操作性。OSIRIS 集经过审查,由国家计划战略委员会批准,并免费向社区发布。进行了一项概念验证研究,使用 300 名患者的队列来实践 OSIRIS 集和通用数据模型。

结论

OSIRIS 小组采用国家和自下而上的方法,定义了一个包含临床和基因组数据最小集的模型,可用于加速肿瘤学中产生的数据共享。该模型依赖于清晰和正式定义的术语,因此也可能使更广泛的国际社会受益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/c33a80e1ca8e/cci-5-cci.20.00094-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/3c79b72adef5/cci-5-cci.20.00094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/61f827c7bb38/cci-5-cci.20.00094-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/3758deb20533/cci-5-cci.20.00094-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/c33a80e1ca8e/cci-5-cci.20.00094-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/3c79b72adef5/cci-5-cci.20.00094-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/61f827c7bb38/cci-5-cci.20.00094-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/3758deb20533/cci-5-cci.20.00094-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a072/8140800/c33a80e1ca8e/cci-5-cci.20.00094-g006.jpg

相似文献

1
OSIRIS: A Minimum Data Set for Data Sharing and Interoperability in Oncology.OSIRIS:肿瘤学中用于数据共享和互操作的最小数据集。
JCO Clin Cancer Inform. 2021 Mar;5:256-265. doi: 10.1200/CCI.20.00094.
2
Precision Oncology Core Data Model to Support Clinical Genomics Decision Making.精准肿瘤学核心数据模型,以支持临床基因组学决策制定。
JCO Clin Cancer Inform. 2023 Apr;7:e2200108. doi: 10.1200/CCI.22.00108.
3
Improving Cancer Data Interoperability: The Promise of the Minimal Common Oncology Data Elements (mCODE) Initiative.改善癌症数据互操作性:最小共同肿瘤学数据元素 (mCODE) 倡议的承诺。
JCO Clin Cancer Inform. 2020 Oct;4:993-1001. doi: 10.1200/CCI.20.00059.
4
Fast Healthcare Interoperability Resources (FHIR) for Interoperability in Health Research: Systematic Review.用于健康研究互操作性的快速医疗保健互操作性资源(FHIR):系统评价
JMIR Med Inform. 2022 Jul 19;10(7):e35724. doi: 10.2196/35724.
5
A methodology for a minimum data set for rare diseases to support national centers of excellence for healthcare and research.一种用于罕见病的最小数据集的方法,以支持国家医疗保健和研究卓越中心。
J Am Med Inform Assoc. 2015 Jan;22(1):76-85. doi: 10.1136/amiajnl-2014-002794. Epub 2014 Jul 18.
6
The Architecture of a Feasibility Query Portal for Distributed COVID-19 Fast Healthcare Interoperability Resources (FHIR) Patient Data Repositories: Design and Implementation Study.用于分布式新冠肺炎快速医疗保健互操作性资源(FHIR)患者数据存储库的可行性查询门户架构:设计与实施研究
JMIR Med Inform. 2022 May 25;10(5):e36709. doi: 10.2196/36709.
7
Data Integration for Future Medicine (DIFUTURE).未来医学数据集成(DIFUTURE)
Methods Inf Med. 2018 Jul;57(S 01):e57-e65. doi: 10.3414/ME17-02-0022. Epub 2018 Jul 17.
8
The project data sphere initiative: accelerating cancer research by sharing data.项目数据领域计划:通过数据共享加速癌症研究
Oncologist. 2015 May;20(5):464-e20. doi: 10.1634/theoncologist.2014-0431. Epub 2015 Apr 15.
9
Streamlining intersectoral provision of real-world health data: a service platform for improved clinical research and patient care.优化跨部门真实世界健康数据的提供:一个用于改善临床研究和患者护理的服务平台。
Front Med (Lausanne). 2024 Jun 5;11:1377209. doi: 10.3389/fmed.2024.1377209. eCollection 2024.
10
Uncovering Harmonization Potential in Health Care Data Through Iterative Refinement of Fast Healthcare Interoperability Resources Profiles Based on Retrospective Discrepancy Analysis: Case Study.基于回顾性差异分析,通过快速医疗保健互操作性资源概况的迭代优化来挖掘医疗保健数据中的协调潜力:案例研究
JMIR Med Inform. 2024 Jul 23;12:e57005. doi: 10.2196/57005.

引用本文的文献

1
Informatics at the Frontier of Cancer Research.癌症研究前沿的信息学
Cancer Res. 2025 Aug 15;85(16):2967-2986. doi: 10.1158/0008-5472.CAN-24-2829.
2
Making the Case for an International Childhood Cancer Data Partnership.推动建立国际儿童癌症数据伙伴关系的理由。
J Natl Cancer Inst. 2025 Jan 12. doi: 10.1093/jnci/djaf003.
3
The 1+Million Genomes Minimal Dataset for Cancer.癌症的100万基因组最小数据集

本文引用的文献

1
Recommendations for patient similarity classes: results of the AMIA 2019 workshop on defining patient similarity.患者相似性分类推荐:AMIA 2019 定义患者相似性专题研讨会的成果。
J Am Med Inform Assoc. 2020 Nov 1;27(11):1808-1812. doi: 10.1093/jamia/ocaa159.
2
Barriers to accessing public cancer genomic data.获取公共癌症基因组数据的障碍。
Sci Data. 2019 Jun 20;6(1):98. doi: 10.1038/s41597-019-0096-4.
3
Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
Nat Genet. 2024 May;56(5):733-736. doi: 10.1038/s41588-024-01721-x.
4
Development of a Secure Web-Based Medical Imaging Analysis Platform: The AWESOMME Project.开发安全的基于网络的医学影像分析平台:AWESOMME 项目。
J Imaging Inform Med. 2024 Oct;37(5):2612-2626. doi: 10.1007/s10278-024-01110-0. Epub 2024 Apr 30.
5
Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research.Consore:一个强大的联邦数据挖掘工具,推动法国研究网络加速癌症研究。
Int J Environ Res Public Health. 2024 Feb 7;21(2):189. doi: 10.3390/ijerph21020189.
6
UNCAN.eu: Toward a European Federated Cancer Research Data Hub.UNCAN.eu:迈向欧洲联邦癌症研究数据中心
Cancer Discov. 2024 Jan 12;14(1):30-35. doi: 10.1158/2159-8290.CD-23-1111.
7
From data strategy to implementation to advance cancer research and cancer care: A French comprehensive cancer center experience.从数据战略到实施以推进癌症研究和癌症护理:一家法国综合性癌症中心的经验。
PLOS Digit Health. 2023 Dec 19;2(12):e0000415. doi: 10.1371/journal.pdig.0000415. eCollection 2023 Dec.
8
Clinical Informatics Approaches to Facilitate Cancer Data Sharing.临床信息学方法促进癌症数据共享。
Yearb Med Inform. 2023 Aug;32(1):104-110. doi: 10.1055/s-0043-1768721. Epub 2023 Jul 6.
9
A Digital Solution for an Advanced Breast Tumor Board: Pilot Application Cocreation and Implementation Study.一种用于高级乳腺癌多学科诊疗团队的数字解决方案:试点应用共创与实施研究
JMIR Cancer. 2023 May 18;9:e39072. doi: 10.2196/39072.
10
Precision Oncology Core Data Model to Support Clinical Genomics Decision Making.精准肿瘤学核心数据模型,以支持临床基因组学决策制定。
JCO Clin Cancer Inform. 2023 Apr;7:e2200108. doi: 10.1200/CCI.22.00108.
分子筛选计划,以选择基于分子的推荐疗法用于转移性癌症患者:来自 ProfiLER 试验的分析。
Ann Oncol. 2019 May 1;30(5):757-765. doi: 10.1093/annonc/mdz080.
4
An Architecture for Translational Cancer Research As Exemplified by the German Cancer Consortium.以德国癌症联盟为例的转化性癌症研究架构
JCO Clin Cancer Inform. 2018 Dec;2:1-8. doi: 10.1200/CCI.17.00062.
5
American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives.美国癌症研究协会基因组证据肿瘤信息交换项目:从启动到首次数据发布及未来——经验教训与成员机构观点
JCO Clin Cancer Inform. 2018 Dec;2:1-14. doi: 10.1200/CCI.17.00083.
6
Status of Lung Cancer Data Collection in Europe.欧洲肺癌数据收集状况
JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.17.00052.
7
CancerLinQ: Origins, Implementation, and Future Directions.癌症LinQ:起源、实施及未来方向。
JCO Clin Cancer Inform. 2018 Dec;2:1-7. doi: 10.1200/CCI.17.00060.
8
Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy.局限性黏液纤维肉瘤:手术切缘和辅助放疗的作用。
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):399-406. doi: 10.1016/j.ijrobp.2018.05.055. Epub 2018 Jun 2.
9
Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers.常见和罕见肉瘤组织学亚型的表现和结局:10262 例局限性内脏/软组织肉瘤患者在参考中心治疗的研究。
Cancer. 2018 Mar 15;124(6):1179-1187. doi: 10.1002/cncr.31176. Epub 2017 Dec 6.
10
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial.基于肿瘤分子谱的分子靶向治疗与常规治疗比较治疗难治性癌症患者的随机 II 期试验:来自 SHIVA 试验的交叉分析。
Ann Oncol. 2017 Mar 1;28(3):590-596. doi: 10.1093/annonc/mdw666.